Risk factors for myelosuppression in chronic phase CML patients treated with Imatinib mesylate (STI571).

被引：0
|
作者：
Mauro, MJ
O'Dwyer, ME
Kurilik, G
Blasdel, C
Farnsworth, M
Fong, D
Hsieh, YC
Mori, M
Ford, JM
Druker, BJ
机构：
[1] Oregon Hlth Sci Univ, Leukemia Ctr, Portland, OR 97201 USA
[2] Univ Hong Kong, Clin Trials Ctr, Hong Kong, Hong Kong, Peoples R China
[3] Novartis Pharma, Basel, Switzerland
来源：
BLOOD | 2001年 / 98卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
585
引用
收藏
页码：139A / 139A
页数：1
相关论文
共 50 条
  • [1] Lack of cytogenetic response is an adverse prognostic factor for relapse of chronic phase CML patients treated with imatinib mesylate (STI571).
    O'Dwyer, M
    Mauro, MJ
    Blasdel, C
    Farnsworth, M
    Kurilik, G
    Fong, D
    Hsieh, YC
    Mori, M
    Capdeville, R
    Druker, BJ
    BLOOD, 2001, 98 (11) : 137A - 138A
  • [2] Imatinib mesylate (STI571) for myeloid malignancies other than CML
    Krystal, GW
    LEUKEMIA RESEARCH, 2004, 28 : S53 - S59
  • [3] RNAi meets imatinib mesylate (STI571)
    Eder, M
    Scherr, M
    BLOOD, 2003, 102 (06) : 1942 - 1942
  • [4] Imatinib mesylate (STI571) in CML patients after autologous peripheral blood stem cell transplantation
    Mahmoud, HK
    El-Emary, M
    Nazier, AA
    El-Haddad, A
    Fahmy, OA
    El-Sayed, N
    AbdMooti, M
    Nasser, A
    Sobhy, A
    El-Nahass, Y
    BONE MARROW TRANSPLANTATION, 2006, 37 : S231 - S231
  • [5] STI571 (imatinib mesylate): the tale of a targeted therapy
    Thambi, P
    Sausville, EA
    ANTI-CANCER DRUGS, 2002, 13 (02) : 111 - 114
  • [6] Hematological and cytogenetic response to imatinib (STI571) in chronic phase patients with CML in a single center: Results and predictive factors.
    Leguay, T
    Cony-Makhoul, P
    Faberes, C
    Boiron, JM
    Bilhou-Nabera, C
    Praloran, V
    Marit, G
    Berthaud, P
    Reiffers, J
    Mahon, FX
    BLOOD, 2001, 98 (11) : 261B - 261B
  • [7] Treatment of accelerated phase of Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML AP) with imatinib mesylate (STI571).
    Kantarjian, HM
    O'Brien, S
    Cortes, J
    Faderl, S
    Giles, F
    Thomas, D
    Garcia-Manero, G
    Albitar, M
    Rios, MB
    Shan, J
    Issa, JP
    Resta, D
    Capdeville, R
    Keating, MJ
    Freireich, EJ
    Talpaz, M
    BLOOD, 2001, 98 (11) : 141A - 141A
  • [8] Inhibition of multiple myeloma proliferation by imatinib mesylate (STI571).
    Pandiella, A
    Carvajal, X
    Tabera, S
    Mateo, G
    San Miguel, JF
    BLOOD, 2002, 100 (11) : 601A - 601A
  • [9] Growth factor mobilization of CD34+ PBSC in CML patients treated with imatinib (STI571).
    Maziarz, RT
    Chauncey, TR
    Capdeville, R
    Druker, BJ
    Seelig, F
    BLOOD, 2001, 98 (11) : 738A - 738A
  • [10] Imatinib mesylate (STI571) in patients with chronic myeloid leukemia in chronic phase previously submitted to autologous stem cell transplantation.
    Cervantes, F
    Hernández-Boluda, JC
    Odriozola, J
    Camós, M
    Villalón, L
    Martínez-Climent, JA
    del Campo, R
    García-Conde, J
    Montserrat, E
    BLOOD, 2002, 100 (11) : 318B - 318B
12345